OneSource Specialty Pharma Limited (NSE:ONESOURCE)
India · Delayed Price · Currency is INR | Market Cap | 185.69B -17.8% |
| Revenue (ttm) | 15.43B +4.3% |
| Net Income | -486.20M |
| EPS | -4.05 |
| Shares Out | 114.65M |
| PE Ratio | n/a |
| Forward PE | 35.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 430,234 |
| Open | 1,678.00 |
| Previous Close | 1,688.30 |
| Day's Range | 1,601.50 - 1,692.90 |
| 52-Week Range | 1,057.00 - 2,026.50 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 2,056.00 (+27.15%) |
| Earnings Date | Jul 24, 2026 |
About NSE:ONESOURCE
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pe... [Read more]
Financial Performance
In fiscal year 2026, NSE:ONESOURCE's revenue was 14.22 billion, a decrease of -1.61% compared to the previous year's 14.45 billion. Losses were -738.03 million, 310.7% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ONESOURCE stock is "Buy." The 12-month stock price target is ₹2,056, which is an increase of 27.15% from the latest price.
News
OneSource Specialty Pharma Transcript: Q1 26/27
Q1 FY 2027 saw 37% revenue and 39% EBITDA growth year-over-year, driven by semaglutide launches, new contracts, and capacity expansions. The company reaffirmed FY 2028 guidance and expects continued growth from biologics, drug device, and soft gelatin segments.
OneSource Specialty Pharma Quarterly report: Q1 2027
OneSource Specialty Pharma has published its Q1 2027 quarterly earnings report on July 25, 2026.
OneSource Specialty Pharma Slides: Q1 2027
OneSource Specialty Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 25, 2026.
OneSource Specialty Pharma Transcript: Q4 25/26
Q4 FY 2026 saw a 47% sequential revenue jump and a sharp EBITDA recovery, driven by semaglutide launches and capacity expansion. FY 2028 guidance of $400 million revenue and 40% EBITDA margin was reiterated, with strong demand and new approvals in key markets supporting future growth.
OneSource Specialty Pharma Slides: Q4 2026
OneSource Specialty Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
OneSource Specialty Pharma Quarterly report: Q4 2026
OneSource Specialty Pharma has published its Q4 2026 quarterly earnings report on May 13, 2026.
OneSource Specialty Pharma Transcript: Q3 25/26
Q3 FY 2026 saw a 26% revenue decline due to delayed Canadian approvals, impacting DDC segment results and EBITDA. Despite near-term softness, robust demand, capacity expansion, and strong customer partnerships support confidence in achieving FY 2028 guidance of $400 million revenue and $160 million EBITDA.
OneSource Specialty Pharma Slides: Q3 2026
OneSource Specialty Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 23, 2026.
OneSource Specialty Pharma Quarterly report: Q3 2026
OneSource Specialty Pharma has published its Q3 2026 quarterly earnings report on January 23, 2026.
OneSource Specialty Pharma Transcript: Q2 25/26
Q2 FY26 saw 12% revenue growth and 37% EBITDA growth, with margins expanding to 28%. Capacity is fully sold out for DDCs, and biologics demand is surging, prompting accelerated expansion. FY 2028 revenue guidance is reiterated at $500 million, with strong global demand and ongoing regulatory uncertainties.
OneSource Specialty Pharma Slides: Q2 2026
OneSource Specialty Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 11, 2025.
OneSource Specialty Pharma Quarterly report: Q2 2026
OneSource Specialty Pharma has published its Q2 2026 quarterly earnings report on November 11, 2025.
OneSource Specialty Pharma Transcript: Q1 25/26
Q1 FY 2026 saw 12% revenue growth and a 37% rise in EBITDA, with strong performance in the DDC segment and robust customer demand driving accelerated capacity expansion. Strategic moves include evaluating acquisitions of Polish and Baroda facilities and a new partnership with Xbrane, positioning the company for significant growth in H2 and beyond.
OneSource Specialty Pharma Quarterly report: Q1 2026
OneSource Specialty Pharma has published its Q1 2026 quarterly earnings report on August 4, 2025.
OneSource Specialty Pharma Slides: Q1 2026
OneSource Specialty Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 4, 2025.